NCT03582488
Longitudinal Imaging Biomarkers of Disease Progression in DLB
Enrolling by Invitation
PHASE4Ages 18+InterventionalDiagnosticKejal KantarciInvestigator-initiated
~135 participants
Updated 2026-03-19 on ClinicalTrials.gov
What's tested:18F-Flortaucipir
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of change in 18F-Flortaucipir PET imaging and Pittsburgh compound-B PET imaging
Measured over Will be assessed 3 times annually over at least three years
Conditions
Where it's being run
2 sites across 2 statesFlorida1
Minnesota1
Study leadership
- Kejal Kantarci, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Diagnosis of probable DLB, at least 18 years of age, reliable informant who personally speaks with or sees the participant at least weekly, sufficiently fluent in English, must be willing and able to consent to the protocol and undergo up to 6 visits over 5 years, willing and able to undergo neuropsychological testing and no contraindication to MRI imaging.
Exclusion
Presence of another neurologic disorder which could impact findings, such as multiple sclerosis, brain tumors, etc., unwilling to return for follow-up yearly and undergo neuropsychological testing and MR imaging, if undergoing Tau imaging cannot have QT Prolongation, do not have a reliable informant.
What this trial measures
- Rate of change in 18F-Flortaucipir PET imaging and Pittsburgh compound-B PET imagingWill be assessed 3 times annually over at least three years
Cortical 18F-Flortaucipir and Global cortical Pittsburgh compound-B uptake will be measured in each participant over three years